Management of Virologic Failure and HIV Drug Resistance

• Autores: Suzanne M. McCluskey, Mark J. Siedner, Vincent C. Marconi
• Localización: Infectious disease clinics of North America, ISSN 0891-5520, Vol. 33, Nº. 3, 2019 (Ejemplar dedicado a: HIV), págs. 743-767
• Idioma: inglés
• Texto completo no disponible (Saber más ...)
• Resumen

  • Approximately 20% of people with HIV in the United States prescribed antiretroviral therapy are not virally suppressed. Thus, optimal management of virologic failure has a critical role in the ability to improve viral suppression rates to improve long-term health outcomes for those infected and to achieve epidemic control. This article discusses the causes of virologic failure, the use of resistance testing to guide management after failure, interpretation and relevance of HIV drug resistance patterns, considerations for selection of second-line and salvage therapies, and management of virologic failure in special populations.